Altimmune, Inc. (ALT)
Automate Your Wheel Strategy on ALT
With Tiblio's Option Bot, you can configure your own wheel strategy including ALT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALT
- Rev/Share 0.0002
- Book/Share 1.9805
- PB 1.9616
- Debt/Equity 0.0982
- CurrentRatio 20.4362
- ROIC -0.5163
- MktCap 342879428.0
- FreeCF/Share -1.0013
- PFCF -4.2028
- PE -3.6075
- Debt/Assets 0.0833
- DivYield 0
- ROE -0.6263
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ALT | Goldman | -- | Sell | -- | $1 | July 10, 2025 |
| Initiation | ALT | William Blair | -- | Market Perform | -- | -- | Feb. 28, 2025 |
| Initiation | ALT | Stifel | -- | Buy | -- | $18 | Jan. 8, 2025 |
News
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Published: October 06, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)-- #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) and reminds investors of the October 6, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm h.
Read More
ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline
Published: October 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Altimmune allegedly misled investors on Pemvidutide's MASH trial, which failed its key fibrosis endpoint, causing shares to plunge 53% on June 26, 2025.
Read More
ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. ("Altimmune" or the "Company") …
Read More
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT) and certain of its officers.
Read More
ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline.
Read More
Portnoy Law Firm Announces Class Action on Behalf of Altimmune, Inc. Investors
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc., ("Altimmune" or the "Company") (NASDAQ: ALT) investors of a class action on behalf of investors that bought securities between August 10, 2023, and June 25, 2025, inclusive (the “Class Period”). Altimmune investors have until October 6, 2025 to file a lead plaintiff motion.
Read More
Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT
Published: September 30, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT.
Read More
DEADLINE APPROACHING: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) (“Altimmune” or the “Company”) following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the “Class Period”).
Read More
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Published: September 29, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 29, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead plaintiff deadline.
Read More
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: September 26, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
Read More
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT) and certain of its officers.
Read More
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
Read More
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 23, 2025 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT).
Read More
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 – ALT
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
Read More
Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
Published: September 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C.
Read More
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT) and certain of its officers.
Read More
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Published: September 16, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 16, 2025 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the "Class Period"), of the important October 6, 2025 lead plaintiff deadline.
Read More
Class Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson Fistel
Published: September 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, announces that a class action lawsuit has been filed on behalf of investors who purchased securities of Altimmune, Inc. (“Altimmune”) (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2025.
Read More
The Gross Law Firm Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT) and certain of its officers.
Read More
Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Altimmune, Inc. (NASDAQ:ALT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:45 AM EDT Company Participants Vipin Garg - President, CEO & Director M. Harris - Chief Medical Officer Presentation Unknown Analyst Hi, everyone.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
Published: September 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT).
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Published: September 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Published: September 01, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 1, 2025 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead plaintiff deadline.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
Published: August 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
About Altimmune, Inc. (ALT)
- IPO Date 2017-05-26
- Website https://altimmune.com
- Industry Biotechnology
- CEO Vipin K. Garg
- Employees 59